Cytek Biosciences (CTKB) Stock Price, News & Analysis

Company Overview

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters. These instruments are complemented by a range of pre-formulated antibody panels, custom reagent kits and data analysis software. Cytek’s offerings are tailored to diverse applications such as immunophenotyping, cell signaling studies, oncology research and translational medicine.

Founded in 2014 and headquartered in Fremont, California, Cytek Biosciences has established a global distribution network serving academic institutions, biopharmaceutical companies and clinical laboratories across North America, Europe and Asia. The company completed its initial public offering in mid-2021, marking a key milestone in its growth strategy. Under the leadership of Dr. Ping Wang, Cytek continues to invest in research and development to extend its spectral cytometry capabilities and broaden its product pipeline.

With a focus on advancing single-cell profiling, Cytek Biosciences aims to accelerate discoveries in immunology, cell therapy and personalized medicine. Its integrated hardware, reagents and software ecosystem provides end users with streamlined workflows, rapid assay development and robust data quality, supporting cutting-edge research and clinical investigations worldwide.

Key Stats

• Today's Range: $3.91 to $4.08
• 50-Day Range: $3.10 to $4.17
• 52-Week Range: $2.37 to $7.63
• Volume: 1.02 million shs
• Average Volume: 1.06 million shs
• Market Capitalization: $501.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.60
• Consensus Rating: Hold

Cytek Biosciences Stock Analysis - MarketRank™

Cytek Biosciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 682nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Cytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Cytek Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytek Biosciences is -78.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytek Biosciences is -78.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cytek Biosciences has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.91% of the float of Cytek Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cytek Biosciences has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Cytek Biosciences has recently increased by 11.18%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytek Biosciences does not currently pay a dividend.

Dividend Growth

Cytek Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.91% of the float of Cytek Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cytek Biosciences has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Cytek Biosciences has recently increased by 11.18%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.65

News Sentiment

Cytek Biosciences has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cytek Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for CTKB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cytek Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.33% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CTKB Stock Analysis - Frequently Asked Questions

How have CTKB shares performed this year?

Cytek Biosciences' stock was trading at $6.49 at the start of the year. Since then, CTKB shares have decreased by 39.3% and is now trading at $3.94.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.05. The company had revenue of $41.46 million for the quarter, compared to the consensus estimate of $43.18 million. Cytek Biosciences had a negative net margin of 3.27% and a negative trailing twelve-month return on equity of 1.66%.
Read the conference call transcript.

How will Cytek Biosciences' stock buyback program work?

Cytek Biosciences' Board of Directors approved a share repurchase program on Monday, December 30th 2024, which authorizes the company to repurchase $50,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 5.9% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

When did Cytek Biosciences IPO?

Cytek Biosciences (CTKB) raised $248 million in an initial public offering on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.

Who are Cytek Biosciences' major shareholders?

Cytek Biosciences' top institutional shareholders include Brown Capital Management LLC (5.59%), Topline Capital Management LLC (4.11%), Geode Capital Management LLC (2.16%) and AQR Capital Management LLC (0.97%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod, William D Mccombe and Jack Ball.
View institutional ownership trends.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cytek Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY) and Humana (HUM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:CTKB
• CIK: 1831915
• Web: www.cytekdev.com
• Phone: 877-922-9835
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cytek Biosciences: $5.60
• High Price Target: $8.00
• Low Price Target: $3.00
• Potential Upside/Downside: +42.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.02 million
• Net Margins: -3.27%
• Pretax Margin: -3.86%
• Return on Equity: -1.66%
• Return on Assets: -1.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.22
• Quick Ratio: 4.55

Sales & Book Value

• Annual Sales: $200.45 million
• Price / Sales: 2.50
• Cash Flow: $0.03 per share
• Price / Cash Flow: 119.30
• Book Value: $2.97 per share
• Price / Book: 1.33

Miscellaneous

• Outstanding Shares: 127,220,000
• Free Float: 114,082,000
• Market Cap: $501.25 million
• Optionable: Optionable
• Beta: 1.36